South Korea
· Delayed Price · Currency is KRW Cytogen Statistics
Total Valuation
Cytogen has a market cap or net worth of KRW 126.42 billion. The enterprise value is 96.84 billion.
| Market Cap | 126.42B |
| Enterprise Value | 96.84B |
Important Dates
The last earnings date was Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytogen has 23.07 million shares outstanding. The number of shares has increased by 20.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 23.07M |
| Shares Change (YoY) | +20.02% |
| Shares Change (QoQ) | +1.36% |
| Owned by Insiders (%) | 21.26% |
| Owned by Institutions (%) | 0.03% |
| Float | 11.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.12 |
| PB Ratio | 2.17 |
| P/TBV Ratio | 3.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.05 |
| EV / Sales | 15.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.30 |
Financial Position
The company has a current ratio of 11.41, with a Debt / Equity ratio of 0.25.
| Current Ratio | 11.41 |
| Quick Ratio | 10.76 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.40 |
| Interest Coverage | -5.92 |
Financial Efficiency
Return on equity (ROE) is -46.56% and return on invested capital (ROIC) is -15.82%.
| Return on Equity (ROE) | -46.56% |
| Return on Assets (ROA) | -13.50% |
| Return on Capital (ROIC) | -15.82% |
| Revenue Per Employee | 121.29M |
| Profits Per Employee | -313.68M |
| Employee Count | 51 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 7.25 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.82% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -56.82% |
| 50-Day Moving Average | 6,684.00 |
| 200-Day Moving Average | 9,210.25 |
| Relative Strength Index (RSI) | 45.51 |
| Average Volume (20 Days) | 224,973 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cytogen had revenue of KRW 6.19 billion and -16.00 billion in losses. Loss per share was -741.47.
| Revenue | 6.19B |
| Gross Profit | 1.34B |
| Operating Income | -11.85B |
| Pretax Income | -16.48B |
| Net Income | -16.00B |
| EBITDA | -9.99B |
| EBIT | -11.85B |
| Loss Per Share | -741.47 |
Balance Sheet
The company has 44.50 billion in cash and 14.62 billion in debt, giving a net cash position of 29.89 billion or 1,295.58 per share.
| Cash & Cash Equivalents | 44.50B |
| Total Debt | 14.62B |
| Net Cash | 29.89B |
| Net Cash Per Share | 1,295.58 |
| Equity (Book Value) | 58.50B |
| Book Value Per Share | 2,522.65 |
| Working Capital | 46.37B |
Cash Flow
In the last 12 months, operating cash flow was -9.57 billion and capital expenditures -844.08 million, giving a free cash flow of -10.42 billion.
| Operating Cash Flow | -9.57B |
| Capital Expenditures | -844.08M |
| Free Cash Flow | -10.42B |
| FCF Per Share | -451.60 |
Margins
Gross margin is 21.59%, with operating and profit margins of -191.49% and -258.63%.
| Gross Margin | 21.59% |
| Operating Margin | -191.49% |
| Pretax Margin | -266.35% |
| Profit Margin | -258.63% |
| EBITDA Margin | -161.44% |
| EBIT Margin | -191.49% |
| FCF Margin | n/a |
Dividends & Yields
Cytogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.02% |
| Shareholder Yield | -20.02% |
| Earnings Yield | -13.53% |
| FCF Yield | -8.24% |
Stock Splits
The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Sep 28, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Cytogen has an Altman Z-Score of 4.71.
| Altman Z-Score | 4.71 |
| Piotroski F-Score | n/a |